COVID-19 impact on early career investigators: a call for action
- PMID: 32503987
- PMCID: PMC7273376
- DOI: 10.1038/s41568-020-0279-5
COVID-19 impact on early career investigators: a call for action
Abstract
The COVID-19 pandemic has broadly impacted biomedical research and health care. Here we discuss current challenges for the cancer research community as they apply to early career investigators (ECIs). We propose a series of collaborative initiatives aimed to sustain ECIs and preserve and accelerate the ability to innovate with long-lasting impact.
Conflict of interest statement
R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo/Lilly, Zentalis, Imago, Mana Therapeutics, Auron, Ajax, Syndax, C4 Therapeutics and Isoplexis. He has consulted for Incyte, Syndax, Celgene and Roche. He receives research support from Prelude Therapeutics and has reviewed grants for Celgene and Gilead. W.K.R. receives research support from Incyte and has clinical trial support from Merck, Genentech, BMS, Pfizer, Novartis, Incyte and Calithera.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
